A person can lawfully possess prescribed cannabis flower in Britain while another person found with the same-looking product may face arrest. That contrast sits at the centre of cannabis legislation in the UK: the law has changed in meaningful but tightly controlled ways, while recreational cannabis remains prohibited.
For patients, consumers and businesses, the practical challenge is separating headlines from the rules that apply on the ground. Medical access, CBD retail, drug-driving enforcement and commercial licensing all operate under different legal frameworks. Treating them as one issue can lead to costly mistakes.
Cannabis legislation remains built around prohibition
Cannabis is controlled as a Class B drug under the Misuse of Drugs Act 1971. It is generally illegal to possess, produce, supply, import or export cannabis without lawful authority. Possession can carry a maximum sentence of five years' imprisonment, an unlimited fine, or both. Producing or supplying cannabis can carry a maximum sentence of 14 years' imprisonment, an unlimited fine, or both.
Those maximum penalties do not describe every case. Sentencing depends on the facts, including quantity, intent, previous convictions, the role played and whether there is evidence of commercial supply. Police responses also vary between forces and circumstances. Some forces use out-of-court disposals or diversion schemes for low-level possession, but these are local enforcement approaches, not legalisation and not a defence to possession.
The distinction matters. A caution, community resolution or diversion offer may avoid prosecution in a particular case, but cannabis remains illegal to possess recreationally throughout the UK. It can still affect employment checks, travel, immigration status and future dealings with police.
Medical cannabis is legal, but access is restricted
Since November 2018, cannabis-based products for medicinal use in humans have been available on prescription in the UK. This did not create a general right to buy cannabis for health reasons. It created a narrow clinical route within a controlled-drug system.
Specialist doctors listed on the General Medical Council's Specialist Register can prescribe unlicensed cannabis-based medicines where they consider this clinically appropriate. In practice, most prescriptions are private. NHS prescribing remains limited, with national guidance generally reserving cannabis-based medicines for specific conditions and circumstances.
A small number of licensed medicines are available for defined uses, including products used in some forms of severe epilepsy, multiple sclerosis spasticity and chemotherapy-related nausea and vomiting. Private clinics may prescribe cannabis flower, oils or other preparations for a wider range of conditions, but a private prescription is not an endorsement of every cannabis product or every claimed benefit. The clinician remains responsible for assessing the patient, potential interactions, treatment history and risk.
Patients should keep prescribed cannabis in its original pharmacy packaging and carry the dispensing label or a copy of the prescription when travelling within the UK. A lawful prescription does not permit a patient to share medication, sell it, grow their own cannabis, or take it abroad without checking the destination country's rules and any export or import requirements.
Nor does a prescription automatically settle every encounter with an employer, landlord, airline or police officer. It provides important legal evidence, but patients should understand the setting-specific rules and keep documentation accessible.
Smoking, vaping and public use
How a product is used matters. Some medical cannabis prescriptions include flower intended for vaporisation, not smoking. Patients should follow the directions on the dispensing label and the advice provided by their prescriber. Using prescribed medicine in public can also raise practical concerns, particularly where smoke-free policies, venue rules or public nuisance issues apply.
The legal position is therefore more precise than the common claim that “medical cannabis is legal”. Prescribed products can be possessed and used as directed. Unprescribed cannabis remains illegal, even where someone self-medicates for a genuine health condition.
CBD law is not a simple percentage test
CBD products are widely sold on British high streets and online, but their availability does not mean they sit outside cannabis controls. CBD itself is not controlled under the Misuse of Drugs Act, yet products containing controlled cannabinoids such as THC may be illegal unless they meet narrow exemption criteria or are authorised in another way.
The frequently repeated “0.2% THC rule” is especially misleading for consumers. It is often linked to rules governing cultivation of certain hemp varieties, rather than a blanket legal retail limit for finished CBD products. Whether a consumer product is lawful can depend on its cannabinoid content, the presence of controlled parts of the plant, its presentation and the relevant regulatory route.
Food and drink products containing CBD are also subject to novel food rules. Businesses need to consider product safety, labelling and regulatory status, not just cannabinoid percentages. For consumers, a clear label and a laboratory certificate are useful indicators of transparency, but neither substitutes for regulatory compliance or proves a product is suitable for a particular health need.
CBD should not be confused with prescribed medical cannabis. Retail CBD is not a licensed medicine, and companies should not make unsubstantiated medical claims for it. That distinction protects consumers from being pushed towards products that may be poorly labelled, inappropriately dosed or unsuitable alongside other medicines.
Drug-driving law creates a separate risk
Cannabis legislation and road traffic law overlap, but they are not identical. In England, Wales and Scotland, it is an offence to drive with specified controlled drugs above set limits in blood. The limit for delta-9-THC is two micrograms per litre of blood, a deliberately low threshold.
There is a statutory medical defence for patients who have been prescribed a medicine and taken it in accordance with medical advice or the product instructions. However, this does not protect anyone driving while impaired. Police can still stop, arrest and investigate a driver where they suspect impairment, and patients may need to demonstrate that their medicine was prescribed and used as directed.
This is one area where casual reassurance can be dangerous. Feeling unaffected is not the same as being fit to drive, and the timing of THC in the body varies between people and products. Patients should discuss driving with their prescriber, read the medicine information carefully and avoid driving if they feel impaired, sleepy, dizzy or unable to concentrate.
Why reform is debated, but not settled
The UK debate is no longer confined to whether cannabis is harmful or harmless. Policymakers are weighing competing concerns: the burden of criminalisation, the safety of an unregulated market, the needs of patients, young people's health, organised crime, policing resources and the prospect of a regulated industry.
Supporters of wider reform argue that prohibition leaves consumers without dependable product standards and directs money towards criminal supply networks. They also point to the unequal impact of enforcement and the mismatch between medical access on paper and the cost of private treatment in practice.
Those urging caution raise legitimate questions about high-potency products, adolescent use, mental health risks for vulnerable people, advertising, road safety and the commercial incentives of a large legal market. International examples offer evidence, but they are not plug-and-play models. Canada, US states, Germany and other jurisdictions have adopted different systems shaped by their own constitutional, healthcare and policing arrangements.
For the UK, any substantial change would require more than a political announcement. It would involve revisiting controlled-drug rules, licensing, product testing, taxation, retail access, criminal records, workplace policy and public-health safeguards. The detail would determine whether reform improved safety and equity or simply created another confusing market.
What this means for people making decisions now
The safest approach is to act on the law as it currently stands, rather than on rumours about decriminalisation or what appears to be openly sold elsewhere. Do not assume a CBD product is equivalent to medical cannabis. Do not assume a medical prescription permits international travel. Do not assume a police diversion scheme makes possession lawful. And do not assume prescribed cannabis removes all drug-driving risk.
For prospective patients, the useful questions are clinical and practical: whether there is a suitable indication, what evidence supports the treatment, how much it will cost, what side effects are possible, and how it may affect work or driving. For consumers, the priority is transparent products and realistic claims. For businesses, compliance must extend beyond branding and THC figures to licensing, safety, advertising and the precise status of every product.
Cannabis policy will continue to move through courts, clinics, Parliament and local policing decisions. Until the law changes, informed caution is not a barrier to progress - it is how patients and consumers protect themselves while demanding a clearer, fairer system.
